ESC Premium Access

State of the Art - PCSK9 in inhibitors therapy in clinical therapy

Congress Presentation

About the speaker

Professor Stephen Nicholls

Monash University, Melbourne (Australia)
52 presentations
4 followers

4 more presentations in this session

The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

Speaker: Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)

Thumbnail

The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.

Speaker: Mrs A. Tsouka (Ioannina, GR)

Thumbnail

Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use

Speaker: Doctor S. Mulverstedt (Copenhagen, DK)

Thumbnail

Positioning PCSK9 inhibitors therapy in clinical practice.

Speaker: Professor K. Ray (London, GB)

Thumbnail

Access the full session

PCSK9 inhibitors: from cells to patients

Speakers: Professor S. Nicholls, Doctor O. Itzhaki Ben Zadok, Mrs A. Tsouka, Doctor S. Mulverstedt, Professor K. Ray
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by